July 25, 2024 by The University of Hong Kong Global price of biosimilar infliximab in July 2022. Credit: JAMA Network Open (2024). DOI: 10.1001/jamanetworkopen.2024.18800A research team from the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) performed a cost-effectiveness analysis of treatment strategies for patients in Hong Kong with rheumatoid arthritis. The...
Tag: <span>biosimilars</span>
Post
Biosimilars Are Effective and Safe in Treating Psoriasis
Elena Riboldi July 05, 2023 A systematic literature review published in JAMA Dermatology provides proof that biosimilar drugs are safe and effective in treating psoriasis. An analysis of clinical studies that compared approved biological drugs (so-called originator drugs) with their biosimilar counterparts has failed to find clinically meaningful differences between the two with respect to efficacy and adverse events. This...
Post
Cardinal Health predicts 2022 to be turning point for biosimilars in the US
CARDINAL HEALTH DUBLIN, OHIO – Feb 7, 2022 — Today Cardinal Health published its 2022 Biosimilars Report: The U.S. Journey and Path Ahead, a publication that brings together the latest industry data on biosimilar utilization and payer coverage with survey data from healthcare providers, and views from leading physicians and experts on biosimilars. The report delivers robust...